contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lidds-has-decided-to-write-down-intangible-assets

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

LIDDS

GOTHENBURG, SWEDEN – The board of directors of LIDDS AB (publ) has, taking into account the principle of prudence, decided to write down the book values of all intangible assets in LIDDS AB ...

<div class="mfn-preamble"><p><strong>GOTHENBURG, SWEDEN – The board of directors of LIDDS AB (publ) has, taking into account the principle of prudence, decided to write down the book values of all intangible assets in LIDDS AB and Noviga Research AB as of 2024-12-31.</strong></p></div><div class="mfn-body"><p>Following the board's decision on April 2, to terminate further development of the project areas Nanodotax, Nanoimod and NOV 202, the board has decided to write down the book values of intangible assets regarding development work and patents. Even though there may be significant values for these assets in the context of sales, the board has decided to take the principle of prudence into account. The write-downs will take place as of year-end 2024/2025, which will result in a deviation for the annual report compared to the published year-end report 2024.<br><br>For LIDDS AB, the impairment will amount to SEK 1.4 MSEK and for Noviga Research AB to SEK 1.2 MSEK. After the impairments, the carrying amount of intangible assets amounts to 0 SEK in both companies.</p></div><div class="mfn-footer mfn-d04cce74190d"><p><strong class="mfn-heading-1">For additional information, please contact</strong></p><hr><p>Mats Wiking, CEO and CFO<br>Phone: +46 (0)70 620 04 00<br>E-mail: mats.wiking<a rel="noopener" href="mailto:jenni.bjornulfson@liddspharma.com">@liddspharma.com</a></p><p>Daniel Lifveredson, Chairman of the Board<br>Telefon: +46 (0) 70-916 21 01<br>Email: <a rel="noopener" href="mailto:d.li@excore.com">d.li@excore.com</a></p><p>LIDDS’ Certified Adviser is Redeye AB</p></div><div class="mfn-footer mfn-about mfn-dcb9e4cb41ff"><p><strong class="mfn-heading-1">LIDDS in brief:</strong></p><hr><p>LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-10 13:30 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/dc0149af-4e00-4b15-b2f4-ad020084f005/lidds-has-decided-to-write-down-intangible-assets.pdf" class="mfn-generated mfn-primary">LIDDS has decided to write-down intangible assets</a></p></div>